AV Remdesivir
32223926 2020. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING
32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
32258351 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
32054787 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
32239125 2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2
32358203 ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
32145386 ä. Remdesivir as a possible therapeutic option for the COVID-19
32247927 ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
32321732 2020. Remdesivir in covid-19
32357949 2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers
32350436 2020. Hopes rise for coronavirus drug remdesivir
32483554 ä. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
32281114 2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
32401466 2006. Remdesivir
32456606 2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.
32503874 2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
32458279 2020. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
32396771 2020. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary.
32397906 2020. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.
32439198 2020. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
32513665 2020. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
32418190 2020. Early experience with remdesivir in SARS-CoV-2 pneumonia.
32521159 2020. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
32468196 2020. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
32515337 2020. [Remdesivir til behandling af COVID-19-pneumoni].
32516797 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
32412709 2020. Compassionate Use of Remdesivir in Covid-19. Reply.
32412708 2020. Compassionate Use of Remdesivir in Covid-19.
32412707 2020. Compassionate Use of Remdesivir in Covid-19.
32412706 2020. Compassionate Use of Remdesivir in Covid-19.
32412705 2020. Compassionate Use of Remdesivir in Covid-19.
32506110 2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
32459919 2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
32446287 2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.
32492200 2020. Remdesivir and Tocilizumab: Mix or Match.
32423584 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
32423580 2020. Remdesivir for COVID-19: challenges of underpowered studies
